Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Marketplace

Streamlined workflow for Roche HPV test, 8/13:86

The FDA has approved a workflow process for Roche Diagnostics’ Cobas HPV test that allows sample processing from the primary sample collection vial after it has been used for cytology (Pap) testing. Labs can load the same vial used for a ThinPrep Pap test directly onto the Cobas 4800 system for high-risk HPV and individual HPV 16 and 18 genotype testing. The workflow option uses a special primary vial rack for the Cobas 4800. The Cobas HPV test, approved by

Supernova antibodies, 8/13:86

Biocare Medical’s Supernova antibodies contain a higher antibody concentration than standard predilutes. Clients now have the option of preserving limited tissue specimens while still providing multi-antigen identification in about the same time as an antibody cocktail. This is achieved using Supernova antibodies in sequential incubations combined with Biocare’s double stain detection. Unique cocktails can also be created with ease as Supernova antibodies have been prepared in optimal diluents for specific tissue types. Supernova antibodies require between 10- and 20-minute incubations.

Chemo exposure optimization assays, 7/13:109

Saladax Biomedical has been certified as a registered CLIA laboratory by the Office of Clinical Standards and Quality, a part of CMS that regulates lab testing performed on humans. The CLIA certification and approval allows the company to begin clinical laboratory operations for its MyCare product portfolio at facilities in Bethlehem, Pa.

Pleural fluid pH testing, 7/13:109

Siemens Healthcare Diagnostics has obtained FDA clearance to offer pleural fluid pH testing on its RapidPoint 500 blood gas system. The addition of pleural fluid pH testing to the RapidPoint 500 complements the analyzer’s critical care menu, which includes blood gas, electrolyte, glucose, lactate, and full CO-oximetry tests, including neonatal total bilirubin and total hemoglobin.

Galectin-3 cited as biomarker of myocardial fibrosis, 7/13:109

BG Medicine’s galectin-3 testing has been recognized in the 2013 American College of Cardiology Foundation and American Heart Association (ACCF/AHA) Guideline for the Management of Heart Failure, which is designed to assist clinicians in selecting the best management strategy for patients and provides analysis of prevention, diagnosis, risk stratification, and treatment data.

LC-MS system, 7/13:109

Thermo Fisher Scientific’s Orbitrap Fusion Tribrid liquid chromatography-mass spectrometry (LC-MS) system combines its quadrupole, Orbitrap, and linear ion trap mass analyzers in a “Tribrid” architecture that analyzes complex biological samples.

NMR lipoprotein particle testing, 7/13:109

Available from LipoScience is NMR (nuclear magnetic resonance) lipoprotein particle testing using the company’s Vantera clinical analyzer through Mayo Medical Laboratories. NMR lipoprotein testing on the Vantera analyzer will be accessible to Mayo Clinic physicians and patients and other hospital clients of Mayo Medical Laboratories.

Expansion of state licensure for BRAF assay, 7/13

Beckman Coulter Genomics’ BRAF assay has been granted clinical laboratory licenses in Pennsylvania, Maryland, Rhode Island, and Massachusetts. CLIA certification, plus licensure in those states, allows Beckman to accept clinical samples for genetic sequencing—the most technically complex CLIA category—and provide those results to physicians to use in treating, diagnosing, and preventing disease in patients.

IncellDx to offer HPV test in China, 7/13:109

IncellDx has reached an agreement with Kindstar Global to offer its proprietary laboratory test for the detection of oncogenic HPV E6, E7 mRNA in China. Kindstar is a large esoteric diagnostic testing business.

MARKETPLACE

TRENDING